Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.67 |
| ▸ | CNR2 | P34972 | 4/20 | 0.62 |
| ▸ | CYP2A13 | Q16696 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.52 |
| ▸ | PTAFR | P25105 | 1/20 | 0.51 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.51 |
| ▸ | PDE2A | O00408 | 1/20 | 0.50 |
| ▸ | PDE6D | O43924 | 1/20 | 0.50 |
| ▸ | PDE6A | P16499 | 1/20 | 0.50 |
| ▸ | PDE6G | P18545 | 1/20 | 0.50 |
| ▸ | PDE6B | P35913 | 1/20 | 0.50 |
| ▸ | PDE6C | P51160 | 1/20 | 0.50 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.50 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4649570 | 0.85 | SIGMAR1 (0.62) | CNR2SMN1; SMN2KMT2A | |
| SCHEMBL14060063 | 0.82 | CYP2A13 (0.50) | HRH3CNR2CYP2A13SMN1; SMN2TSHR | |
| SCHEMBL4473916 | 0.82 | HRH3 (0.63) | HRH3CNR2CYP2A13SMN1; SMN2TSHR | |
| 4-(Biphenyl-4-Ylmethyl)Morpholine SCHEMBL1691308 | 0.82 | HRH3 (0.85) | HRH3SMN1; SMN2TSHRNPC1RAB9A | |
| SCHEMBL27966164 | 0.81 | SIGMAR1 (0.62) | HRH3CNR2MEN1KMT2A | |
| SCHEMBL8070873 | 0.80 | PKM (0.56) | CNR2NPC1TP53RAB9AMEN1 | |
| SCHEMBL4478068 | 0.80 | CNR2 (0.65) | HRH3CNR2SMN1; SMN2TSHRNPC1 | |
| SCHEMBL4477687 | 0.80 | CNR2 (0.63) | HRH3CNR2CYP2A13SMN1; SMN2TSHR | |
| SCHEMBL7699664 | 0.79 | HRH3 (0.55) | HRH3CNR2CYP2A13SMN1; SMN2TSHR | |
| SCHEMBL15467001 | 0.79 | HRH3 (0.87) | HRH3CYP2A13SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595397-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-29 | — | — | US | disclosed |
| US-7595397-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-29 | — | — | US | disclosed |
| US-7595397-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-29 | — | — | US | disclosed |
| EP-1966132-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-09-10 | — | — | EP | disclosed |
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| WO-2007070760-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070760-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | CNR1, CNR2, ARRB1 | HRH3 283/4885CNR2 2/4885CYP2A13 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.